References
- Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. doi:https://doi.org/10.1056/NEJMoa1409547.
- Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107–118. doi:https://doi.org/10.1016/S2213-2600(16)30427-1.
- Jennings MT, Dezube R, Paranjape S, et al. An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor. Annals Am Thorac Soc. 2017;14(11):1662–1666. doi:https://doi.org/10.1513/AnnalsATS.201701-058OC.
- Hubert D, Chiron R, Camara B, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16(3):388–391. doi:https://doi.org/10.1016/j.jcf.2017.03.003.
- Taylor-Cousar JL, Jain M, Barto TL, et al. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018;17(2):228–235. doi:https://doi.org/10.1016/j.jcf.2017.09.012.
- Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:https://doi.org/10.1183/09031936.00080312.
- Lieberman J, Rodbard S. Low blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat? Ann Intern Med. 1975;82(6):806–808. doi:https://doi.org/10.7326/0003-4819-82-6-806.
- Marigowda G, Liu F, Waltz D. Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. J Cyst Fibros. 2017;16(2):246–249. doi:https://doi.org/10.1016/j.jcf.2016.11.001.
- Popowicz N, Wood J, Tai A, et al. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease. J Cyst Fibros. 2017;16(3):392–394. doi:https://doi.org/10.1016/j.jcf.2017.02.009.
- Labaste A, Ohlmann C, Mainguy C, et al. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis. J Cyst Fibros. 2017;16(6):709–712. doi:https://doi.org/10.1016/j.jcf.2017.05.002.
- Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013–2023. doi:https://doi.org/10.1056/NEJMoa1709846.